Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to treat multiple myeloma. The addition of Xpovio to standard-of-care Velcade and dexamethasone also reduced peripheral neuropathy vs. SOC alone, suggesting a safety advantage over rival combinations.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) plans to submit an sNDA next quarter for the oral XPO1 inhibitor to treat second-line relapsed or refractory multiple myeloma (MM). ...